Background
HIV-1 RNA quantitation (viral load) is used to monitor treatment efficacy, helping clinicians make decisions regarding switching or continuing the current antiretroviral therapy (ART). According to HIV treatment guidelines, ART is considered effective when it leads to undetectable HIV-1 RNA in plasma, whereas results above 50 copies/ml may trigger further investigations [1] [2] [3] [4] [5] . Because Abbreviations: AS, Acromterix HIV-1 standards; CV, coefficient of variation; IS, 3rd WHO HIV-1 International Standard; LLOQ, lower limit of quantitation; LTR, long terminal repeat; TMA, transcription mediated amplification.
* this threshold is close to the lower limit of quantitation (LLOQ) of most commercially available assays (20-75 copies/ml), assay performance at low HIV-1 RNA levels can significantly influence management decisions during ART. In the UK, nucleic acid amplification tests are standard practice for monitoring of HIV infection [1] [2] [3] [4] 6] . These assays are largely based on real-time PCR and share similar performance characteristics [7] [8] [9] [10] [11] . Recently the Hologic Aptima HIV-1 Quant Dx assay (Aptima HIV) became commercially available in the UK. Aptima HIV is based on real-time transcription mediated amplification (TMA), a technology with high sensitivity for detection of pathogen RNA [12, 13] .
While PCR-based assays have been evaluated side-by-side in many studies [10, 14, 15] , the performance of Aptima HIV has not yet been compared with that of other assays. UK clinical laboratories are required to validate assay performance prior to implementing any new test in to routine diagnostic use [16] .
Objectives
The aim of this study was to compare the analytical performance of Aptima HIV with that of three PCR-based assays: Abbott RealTime HIV-1 (RealTime), Qiagen artus ® HI Virus-1 QS-RGQ (Artus), and Roche COBAS ® AmpliPrep/COBAS® Taqman HIV-1 Test v2 (CAP/CTM), with a particular focus on samples with low HIV-1 RNA copy number.
Study design

Viral load assays
All HIV-1 RNA assays were performed according to the manufacturer's instructions.
3.1.1. Aptima HIV Plasma (0.75 ml) was transferred into a sample aliquot tube, vortexed and centrifuged at 1000 × g for 10 min prior to loading onto the Panther system which extracted HIV-1 RNA from 0.5 ml of plasma using automated target capture technology, followed by amplification and detection of HIV-1 long terminal repeat (LTR) and pol gene targets (Hologic Inc., San Diego, CA, USA). The reported LLOQ is 30 copies/ml with an upper limit of quantitation of 10 7 copies/ml [17] .
RealTime
Plasma (1 ml) was aliquoted, vortexed and centrifuged at 431 × g for 5 min prior to loading into the Abbott m2000 sample preparation system which extracted HIV-1 RNA from 0.6 ml of plasma, followed by amplification and detection of the HIV-1 integrase gene on the Abbott m2000rt PCR instrument (Abbott Molecular, Inc., Des Plaines, IL, USA). The LLOQ is 40 copies/ml and the upper range of quantitation is 10 7 copies/ml [18].
Artus
RNA was extracted from 1.0 ml of plasma using the Qiagen QIAsymphony SP automated extractor followed by amplification and detection of HIV-1 LTR on the Qiagen Rotor-Gene Q real-time PCR instrument (Qiagen GmbH, Hilden, Germany). The LLOQ is 45 copies/ml and the upper range of quantitation is 4.5 × 10 7 copies/ml [19] .
CAP/CTM v2
Plasma (1.0 ml) was transferred into an input S-tube and loaded onto the Cobas Ampliprep instrument where RNA was extracted from 0.85 ml of sample prior to automated amplification and detection of HIV-1 LTR and gag targets on the COBAS ® Taqman Analyser (Roche Molecular Systems, Inc., Pleasanton, CA, USA). The LLOQ is 20 copies/ml and the upper range of quantitation is 10 7 copies/ml [20].
Evaluation of Acrometrix Standards (AS)
Linearity and accuracy of all four systems was assessed by analysing panels of AS (Acrometrix HIV-1 panel copies/ml, Life Technologies, Carlsbad, CA, USA) in the range 2.00-6.70 log 10 copies/ml. Aptima HIV was further evaluated with triplicate samples constructed from an AS panel diluted 1:3 using Basematrix HIV-1 negative human plasma (SeraCare, Lifescience, US). Linear regression analysis was performed and concordance correlation coefficient calculated.
Evaluation of 3rd WHO International HIV-1 RNA Standards (IS)
Low-level precision of each assay was compared using IS (National Institute for Biological Standards and Control, UK) containing 185,000 IU/ml of HIV-1 subtype B. Nine replicates of 6 IS dilutions in Basematrix were independently extracted and tested on all four systems over three days. The dilutions contained 28, 56, 112, 224, 558 and 1116 IU/ml HIV-1, corresponding to 12.5, 25, 50, 100, 250 and 500 copies/ml, respectively (when using the Qiagen conversion factor of 1 IU/ml = 0.45 copies/ml). Coefficients of variation were calculated at dilution points above the highest LLOQ across the 4 assays (>45 copies/ml). 
Pair-wise comparison of assay performance
Agreement for HIV-1 RNA detection and for categorisation above or below the 50 copies/ml threshold was assessed by calculating the kappa value for each pair-wise comparison. Regression and Bland-Altman analysis were performed on quantitative results and differences were tested using paired t-tests. All analyses were conducted using Microsoft Excel 2010 and MedCalc software v13.3.0.
Results
Accuracy and linearity of assays across the dynamic range
All Aptima HIV measurements were within 0.24 log 10 copies/ml of the Acrometrix target value and data were linear across the dynamic range (precision = 0.9977; accuracy = 0.9972; concordance = 0.9949). Results from all four assays were highly correlated (linear regression analysis; R 2 > 0.99) (Fig. 1 ).
Precision of HIV-1 RNA quantitation using low-level WHO International Standard (IS)
Aptima HIV detected HIV-1 RNA in 8/9 and 9/9 replicates with nominal values 12 and 25 copies/ml, respectively. Quantitative results were reported for 27% Aptima HIV, 33% RealTime, 38% Artus and 28% of CAP/CTM replicates at these two low-level dilution points. Analysis of replicates in the range 50-500 copies/ml showed precision decreased close to the LLOQ in all assays (Table 1) . Aptima HIV coefficient of variation (CV) values were 18-44% for replicates in the range 250-50 copies/ml, although the lowest CV were seen at 500 copies/ml with RealTime (8%) and CAP/CTM (9%). The corresponding value for Aptima HIV was 17% which related to a 1.3 fold change in 95% CI and this increased to 2.1 at 50 copies/ml. Equivalent CV values using log transformed data of the four IS dilutions (1.7, 2.0, 2.4 and 2.7 log 10 copies/ml) were in the range of 2.7-9.1%, 1.3-5.2%, 4.5-15.1% and 1.4-10.2% log copies/ml for Aptima HIV, RealTime, Artus and CAP/CTM. 
External quality assessment panels
Aptima HIV was fully concordant with expected EQA results ( Table 2) . Quantitation of the subtype B dilutions was reproducible using the Aptima HIV assay. Quantitation of subtype C samples varied between assays by up to 0.76 log 10 copies/ml.
Comparison of assay sensitivity with clinical samples
A total of 191 samples from HIV-infected patients were analysed. Aptima HIV detected HIV-1 RNA in 74% samples, similar to the proportion reported positive by CAP/CTM (Table 3) . When categorising clinical samples above or below the 50 copies/ml threshold, 59%, 59%, 56% and 55% were quantified as <50 copies/ml by Aptima HIV, RealTime, Artus and CAP/CTM, respectively (Table 4) 
Analysis of discordant clinical samples
All assays gave at least one discordant result. The four assays had agreement in quantification above 50 copies/ml for 67/191 (35.1%) samples. Aptima HIV, RealTime, Artus and CAP/CTM discrepantly reported 3, 1, 4 and 4 samples as <50 copies/ml when the other three assays gave values above this cutoff. Conversely, the number of samples reported ≥50 copies/ml by only one assay when corresponding results from the other three platforms were all below this threshold were 1 (66 copies/ml), 0, 6 (range 63-166 copies/ml) and 6 (range 55-131 copies/ml) for Aptima HIV, RealTime, Artus and CAP/CTM, respectively. At the 200 copies/ml threshold, 1 (507 copies/ml), 0, 5 (range 241-520 copies/ml) and 3 (range 250-419 copies/ml) discordant samples were identified for Aptima HIV, RealTime, Artus and CAP/CTM, respectively, when the other three assays reported below this value.
Quantitative correlation between Aptima HIV and the PCR assays
Linear regression analysis for all clinical results >LLOQ (n = 87 for Aptima HIV, 84 for RealTime, 86 for Artus and 107 for CAP/CTM) showed good correlation between Aptima HIV and the three PCR assays (R 2 > 0.93) (Supplementary data). Aptima HIV quantified significantly higher than RealTime (P = 0.001) with a mean bias of 0.12 log 10 copies/ml ( Fig. 2A) . Overall, >93% of the paired Aptima HIV results fell within the 95% CI levels of agreement when compared with the PCR assays by Bland-Altman analysis, and limits of agreement were narrowest between Aptima HIV and RealTime at 0.49 log copies/ml either side of the mean. There were 5 discrepant samples outside the 95%CI level of agreement between Aptima HIV and RealTime (2 subtypes B, 2 C and 1 A/B), 5 between Aptima HIV and Artus (1 subtype B, 1 C, 1 D/A, 1 CRF01 AE and 1 unknown), and 3 between Aptima HIV and CAP/CTM (2 subtypes C and 1 CRF02 AG). Of these 11 discrepant samples, 5 had low copy numbers (<3 log 10 copies/ml) and at least 3 were due to an unexpected result by another assay (Table 5) .
Comparison of RealTime or CAP/CTM to Artus also revealed 5 discrepant samples between each PCR assay compared (Table 5) .
Artus quantitation was significantly higher on average than RealTime (P = 0.0001) and CAP/CTM (P = 0.002). Mean differences for RealTime minus Artus, RealTime minus CAP/CTM and CAP/CTM minus Artus were −0.17, −0.05 and −0.14 log copies/ml, respectively (Fig. 2B) .
Discussion
HIV-1 plasma viral load is a routine investigation for monitoring of HIV-1 infected individuals. In a recent report, 77% (58/75) of laboratories reported using commercial real-time PCR assays [21] . Two of the principal real-time assays, Abbott RealTime and Roche CAP/CTM v2, are both FDA-approved and their performance is well documented in the literature [15, [22] [23] [24] [25] [26] [27] [28] [29] . Characteristics of the Qiagen Artus HIV-1 real-time PCR test launched in 2010 on the QS-RGQ system have also been described [10, 30] .
The Aptima HIV-1 Quant Dx assay on the Panther system was approved for European use in the diagnosis and monitoring of HIV-1 infection in November 2014. It is the first commercially available real-time, TMA assay for quantitation of viral RNA levels and the evaluation presented here demonstrated Aptima HIV results are highly correlated with those obtained from real-time PCR technologies. The Aptima HIV test was highly accurate for quantitation of HIV-1 subtype B in the standard panels. Results were similar to those reported by Manak et al. where Aptima HIV quantification was comparable to RealTime and CAP/CTM for all major group M HIV-1 subtypes and four group O isolates [31] .
Linearity can be affected by poor precision and this may be more evident close to the LLOQ of an assay. Overall, Aptima HIV quantitation of IS did not exceed 20% CV, except at 50 copies/ml where variation could represent up to two-fold change in viral load. Below 500 copies/ml, imprecision was observed with all assays but only Artus HIV was significantly less reliable. This is similar to the pattern described previously where Artus HIV had lower reproducibility than RealTime and CAP/CTM [15, 32] . Whilst a higher number of replicates is needed to give a definitive calculation of total imprecision for each platform, the wide limits of agreement observed in Bland-Altman analysis of Artus measurements supports the greater likelihood of analytical variation using this test [33] . Mean quantitation of clinical samples was similar across all assays with observed bias <0.17 log 10 copies/ml. However, it would be prudent not to switch assays interchangeably during patient monitoring where this can be avoided. DHHS refer to optimal suppression below the assay limit of detection, with virological failure as the inability to achieve or maintain HIV-1 RNA load below 200 copies/ml [3] . Both BHIVA and EACS utilise a threshold of 50 copies/ml to define suppression [1, 5] . Here virological failure is defined as inability to achieve <50 copies/ml after 6 months of starting ART, or confirmed rebound >400 copies/ml after suppression below 50 copies/ml. A single blip between 50 and 400 copies/ml is not a cause for clinical concern if preceded and followed by viral loads below 50 copies/ml. Thus low level HIV-1 RNA quantitation impact on patient management.
Whilst inter-assay correlation was high overall, concordance was reduced closer to the lower limits of assay performance. This was emphasised with considerable disagreement between tests to designate complete viral suppression to undetectable levels: HIV-1 RNA was detected by at least one assay in 162/191 (85%) samples whereas the four assays agreed HIV-1 RNA was present in only 92 (48%). Hologic states a lower limit of detection of 13 copies/ml (IS) for the Aptima HIV assay and data presented here confirms the test is highly sensitive with clinical samples. Use of ultra-sensitive assays has demonstrated the presence of very low-level HIV-1 replication even in the presence of intensive therapy and the clinical significance of these findings has been reviewed elsewhere [34] . a Discordant results were in the range: <40 copies/ml. b Discordant results were in the range: <30 copies/ml. c Discordant results were in the range: <45 copies/ml. d Discordant results were in the range: <30-507 copies/ml. e Discordant results were in the range: <20-25 copies/ml. f Discordant results were in the range: <30 copies/ml.
Table 4
Comparison between Aptima HIV and the other assays for quantitation of samples < and ≥50 copies/ml. As such, discrepancies in low-level RNA detection may not represent viral escape but could be attributed to random variation within the confidence intervals at the limit of detection in each assay [32, 35] . Hence, quantitative values in the region 50-400 copies/ml are often investigated further in UK clinical practice with a followup sample requested to confirm viraemia [1] . Aptima HIV identified fewer discordant samples above 50 copies/ml compared to Artus and CAP/CTM. This has potential implications for clinical practice given that fewer patients would be recalled unnecessarily to investigate blips and low-level viraemia. Similar to previous comparison studies testing multiple subtypes, discrepant samples identified by Bland-Altman analysis included those with lower viral loads and non-B subtypes [7] [8] [9] [10] [11] 36] . There may be issues relating to detection of low level viraemia with specific assays. Previous investigators reported transition to the CAP/CTM v2.0 assay was followed by an increase of quantifiable viral loads in patients with prior viral suppression, which were then below the limit of detection in subsequent viral load measurements [29] . Similar to CAP/CTM v2.0, Aptima HIV is a highly sensitive dual-target assay. However, Aptima technology differs in that TMA inherently targets RNA molecules for amplification. This reduces the likelihood of proviral DNA amplification contributing to low-level quantitative signals. Likewise, preferential recovery of RNA over DNA has been proposed for the RealTime HIV protocol [37] . These technological factors may account for some of the variation observed between assays at low viral loads. Variation at low-copy number highlights the importance of selecting an assay with precision across the dynamic range, and of consecutive testing to confirm increases in HIV-1 RNA load. The relationship between variability of low viraemia levels and treatment efficacy is an area of active debate and controlled clinical studies are needed to further understand the significance of blips for patient management [34] . It is vital that dialogue exists between clinic and laboratory to understand and interpret low copy number results. This evidence is needed to guide consensus opinion.
The strength of this study is the use of three commercial comparator PCR assays with Aptima HIV. This allowed direct comparison between the different commercial platforms, easier identification of outlier results in clinical samples and showed that discrepancies can occur with all assays, particularly at low copy number. A weakness is the absence of follow-up data to establish the clinical significance of Aptima HIV results above 50 copies/ml. A post-implementation clinical audit of low-level viraemia is planned in order to address this. To summarise, Aptima HIV has excellent comparative performance across the metrics used in this study (accuracy, precision, subtype detection, clinical sample testing) and provides a useful new tool for monitoring HIV-1 RNA load in clinical laboratories. Aptima HIV results for reliable RNA quantitation at low copy number appear promising, although studies with clinical follow-up are required.
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